Lilly

2Q Revenues: $5.2 billion (+11%)

2Q Earnings: $958.8 million (+44%)

YTD Revenues: $10.0 billion (+12%)

YTD Earnings: $2.0 billion (+73%)

Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve, collectively grew 21% to $1.8 billion, and accounted for 35% of total sales, up from 32% in 2Q07. Zyprexa sales in the quarter were $1.2 billion (+2%). Cymbalta sales were $654.4 million (+26%). Gemzar sales were $440.1 million (+11%). Humalog sales were up 22% to $437.9 million. Cialis sales were $362.2 million (+24%). Alimta sales were up 33% to $275.0 million. Byetta sales were up 25% to $194.7 million in quarter. The company recognized a charge of $35.0 million in quarter for acquired in-process R&D associated with the in-licensing transaction with TransPharma Medical. Restructuring costs and other charges were $88.9 million in the quarter, primarily associated with strategic exit activities related to manufacturing operations.